iPREVENT study
Key information
Chief Investigator: Gary Frost
ICTU Therapeutic area: Other – opiate addiction
ICTU collaboration: Operations; Statistics; Database
Email: iprevent@imperial.ac.uk
Study website: iPREVENT
Social media:
Trial registration:
ISRCTN16299902
Status: Close-out and analysIs
The iPREVENT trial is a randomised, placebo-controlled, double-blind trial to investigate the impact of inulin propionate ester (IPE) on weight gain prevention in adults aged 20 to 40 years at high risk of gaining weight. 270 participants have been randomised to either IPE or inulin control for 12 months. The iPREVENT trial is running at two UK sites; Imperial Clinical Research Facility (CRF) in London - Imperial College Healthcare NHS Trust and Glasgow CRF - NHS Research Scotland.
iPREVENT videos
![iPrevent Animation](/assets/website/images/placeholder/video-placeholder.jpg)
iPrevent Animation
iPrevent Animation long version
![IPE - How It Works](/assets/website/images/placeholder/video-placeholder.jpg)
IPE - How It Works
IPE - How It Works - Douglas Morrison